Overview

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
Phase:
NA
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Chao Yang Hospital
Huazhong University of Science and Technology
Peking Union Medical College Hospital
Peking University Third Hospital
Shandong University
Shengjing Hospital
Tianjin Medical University
Treatments:
Medroxyprogesterone Acetate
Megestrol Acetate
pembrolizumab
sintilimab